KemPharm appoints Christopher A. Posner to board of directors

ZEVRA THERAPEUTICS, INC.

Christopher A. Posner appointed effective November 28, 2022 as Class II director with term expiring at 2023 annual meeting.
Posner is President and CEO of Cara Therapeutics; brings experience in pharmaceutical commercial operations and product management.
Received initial option grant for 22,500 shares vesting over three years; annual cash retainer of $40,000 under non-employee director policy.
Eligible for additional annual option grant of 15,000 shares at each subsequent annual meeting where term continues.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher A. Posner

Director

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2022-11-28
Filed: November 29, 2022, 6:59 PM ET

On November 28, 2022, the board of directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Christopher A. Posner to serve as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher A. Posner was appointed as Director at ZEVRA THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

On November 28, 2022, the board of directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Christopher A. Posner to serve as a director of the Company, effective immediately.

View on SEC.gov

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-028128

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.